Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Spondyloarthritis family · A closer look at PsA

Choosing treatment for psoriatic arthritis

How the affected areas, your health and your goals shape the choice of medicine—and what to check before starting.

Olga Goodman, MD · Sources checked 27 September 2026

Chapter 5 of 21

The essentials

The useful question is: which treatment fits my active disease and my circumstances? Agree on the target, the safety plan and the date for reassessment together.

Start with the problem to be treated

Map swollen joints, painful tendon attachments, swollen fingers or toes, spinal symptoms, skin and nails. Record the activities you want to regain. A small skin area can matter greatly if it affects hands, genitals or sleep. Joint and skin improvement may proceed at different speeds. 1, 2

A treatment plan also includes movement, rehabilitation, cardiovascular health and support for daily life. These measures work alongside medicines when inflammation needs treatment. 3

NSAIDs and local injections

Purpose: NSAIDs can reduce pain and stiffness; a local glucocorticoid injection may help an individual inflamed area. Symptom relief does not by itself show that the whole disease is controlled. 1, 3

Before starting: discuss ulcers or bleeding, kidney disease, blood pressure, cardiovascular disease and other medicines. Do not combine different NSAIDs on your own. Local injections require an assessment of the cause of swelling, including possible infection.

Review: are pain and function improving, and is inflammation still present? EULAR limits NSAID-only treatment to mild disease and a short period; routine oral glucocorticoids are not recommended in its PsA strategy. An existing steroid prescription needs an individual plan, not abrupt self-directed withdrawal. 1

Methotrexate, leflunomide and sulfasalazine

Purpose: conventional disease-modifying drugs are used for peripheral joint arthritis. Methotrexate may also help psoriasis. They are not an established treatment for axial inflammation. 1, 2

Before starting: review blood counts, liver and kidney function as relevant, other medicines, alcohol use and pregnancy plans. Methotrexate for inflammatory arthritis is usually taken once weekly; the prescribed schedule and folate plan must be clear. 4

Review: joint findings, skin, function, tolerability and blood tests. Ask when the dose or route will be reviewed and what happens if the agreed target is missed. Laboratory monitoring is part of treatment, even when you feel well.

Biologics: different targets, different choices

Purpose: examples include TNF inhibitors; IL-17A inhibitors such as secukinumab and ixekizumab; the IL-17A/F inhibitor bimekizumab; IL-12/23 inhibition with ustekinumab; and IL-23 inhibitors such as guselkumab and risankizumab. Abatacept acts through T-cell costimulation. These are examples, not a ranked or exhaustive prescribing list. 2, 3, 5

Before starting: the team checks infections, tuberculosis and hepatitis screening as appropriate, vaccination history and relevant medical conditions. Inflammatory bowel disease or uveitis can change the preferred mechanism; medicines within a broad class are not interchangeable for every associated condition. 1, 2

Review: assess each active area, injection or infusion problems and infections. A clear skin response does not guarantee adequate joint or spinal control. Ask which of your manifestations the proposed drug is expected to treat and which need additional care.

Another approved option for PsA

Tildrakizumab (Ilumya) is now approved in the United States for adults with active psoriatic arthritis. Whether it suits you depends on your disease features, safety assessment and access. 10

PDE4 inhibition: apremilast

Purpose: apremilast is an oral option for active PsA. Its place depends on disease burden, previous treatment and why other options may be unsuitable. It should not become a reason to leave persistent active disease unaddressed. 1, 6

Before starting: discuss kidney function, other medicines, weight and a history of depression. Review nausea or diarrhoea, weight change and mood after starting, alongside the joint and skin response. Seek prompt help for severe mood changes or suicidal thoughts. Ask what improvement would justify continuing. 6

JAK inhibitors: an individual risk discussion

Purpose: oral JAK inhibitors are targeted treatments with PsA indications for particular products. In the United States, relevant arthritis indications place them after inadequate response or intolerance to TNF blockers. Local labels matter. 7

Before starting: discuss serious infection, shingles, cancer, cardiovascular and clotting history, smoking, vaccination and laboratory monitoring. FDA warnings include serious cardiovascular events, cancer, thrombosis and death. The pivotal safety comparison involved older patients with rheumatoid arthritis and cardiovascular risk factors; it is not a numerical forecast for every person with PsA. 7

Review: disease response, blood tests and new symptoms. Ask how your personal risk profile changes the choice, and which symptoms require urgent help. Taking a tablet does not make a treatment inherently gentler than an injection.

TYK2 inhibition: the 2026 Sotyktu update

Deucravacitinib selectively inhibits TYK2. The US Sotyktu label revised in March 2026 includes adults with active psoriatic arthritis. This approval is later than the EULAR 2023 recommendations; approval, guideline positioning and local availability are separate questions. 8

Before starting: check tuberculosis, active or recurrent infections, vaccinations and relevant liver problems; review other medicines. Follow the current local product information. The US label discusses infections and other precautions and notes uncertainty about whether risks observed with JAK inhibition also apply to TYK2 inhibition. It should not be described as risk-free.

Review: joint and skin response, adverse effects and the monitoring required for the individual. Ask why this mechanism fits your situation and how it compares with established alternatives. 8

Sequence, combinations and biosimilars

If the target is missed, first clarify whether the medicine had an adequate trial, whether doses were interrupted and which manifestations remain active. The next step may be a change within a class, a different mechanism or an adjustment to the overall plan. Combining targeted immune therapies is not something to improvise. 1, 2

A biosimilar has no clinically meaningful differences in safety or effectiveness from its reference biologic under the approved conditions of use. Device, formulation and substitution rules may differ. Ask which product you will receive and how to use it; a lower price does not mean weaker treatment. 9

Tell the team early about cost, insurance delays, refrigeration or injection difficulties. A prescription that cannot be obtained or used reliably is an access problem to solve, not proof that the disease resists that medicine.

Leave with a practical plan

Write down: the medicine and schedule; the purpose; tests and vaccinations; what to do during infection or before a procedure; whom to contact; and the review date. Pregnancy planning needs a medicine-specific discussion before treatment changes. Open the relevant Medication Guide for practical use of a medicine already prescribed. 3

Injection day: fact or myth? — Open demo · no registration →

Methotrexate, the friendly way — Open demo · no registration →

Meet the medicine families — Free after registration →

Go deeper

Why there is no single ladder for everyone

Think of two people with the same PsA diagnosis: one mainly has swollen hand joints, while the other has inflammatory spinal symptoms, substantial psoriasis and bowel disease. Counting previous medicines alone cannot settle the next choice. The treatment must fit the active manifestations and associated conditions as well as safety and patient priorities. 1, 2

Regulatory labels define approved uses in a jurisdiction. Recommendations interpret evidence for a clinical strategy. Insurance rules govern access. These three layers can differ; ask which one explains a proposed delay or substitution.

A direct comparison of two medicines

A direct study found a greater chance of a substantial joint response with bimekizumab than with risankizumab. This does not mean it was better for every outcome. Bowel disease, skin symptoms, infections and your treatment goals still influence the choice. 11, 12

Questions for your visit

  1. Which manifestations are active, and what is our target?
  2. Why does this mechanism fit my joints, skin and other conditions?
  3. Which checks and monitoring do I need?
  4. When will we judge the response, and what is plan B?

When to seek urgent help

A painful red eye, light sensitivity or a sudden change in vision needs urgent assessment. A newly hot, swollen joint, especially with fever or feeling unwell, also needs prompt assessment.

Sources & evidence notes

Sources checked 27 September 2026

Drug approvals and availability vary by country. Regulatory updates are identified separately from older recommendations.

  1. Gossec L et al. EULAR recommendations for PsA: 2023 update. Ann Rheum Dis. 2024.
  2. Coates LC et al. GRAPPA treatment recommendations 2021. Nat Rev Rheumatol. 2022.
  3. NIAMS. Psoriatic arthritis: diagnosis, treatment and steps to take.
  4. American College of Rheumatology. Methotrexate: patient information. February 2025.
  5. FDA. Bimzelx (bimekizumab-bkzx): US prescribing information including PsA. 2024.
  6. FDA. Otezla (apremilast): US prescribing information. 2025.
  7. FDA. JAK inhibitors: warnings about serious cardiovascular events, cancer, thrombosis and death.
  8. FDA. Sotyktu (deucravacitinib): US prescribing information, revised March 2026.
  9. FDA. Biosimilar basics for patients.
  10. FDA. ILUMYA US prescribing information revised October 2026. Primary regulatory source; adult active PsA indication and phenotype-specific dosing.
  11. McInnes et al.. BE BOLD at 24 weeks. ACR 2026 abstract 2804; randomized head-to-head trial.
  12. UCB. BE BOLD joint response and safety details. Sponsor report, 9 Nov 2026, explicitly based on the ACR abstract dataset.

Educational information for patients and caregivers. This personal publication is not the clinic portal and does not provide individual diagnosis or treatment. Discuss medication changes with your own care team.

© 2026 Olga Goodman, MD · A RheumaView publication. Copying without attribution prohibited.

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: PsoriasisPsoriatic arthritisSpondyloarthritis